Subcutaneous IVIG for Treatment of Myasthenia Gravis

Rubin, Michael MD

Professor of Clinical Neurology, Weill Cornell Medical College

Neurology Alert 42(9):p 71-72, May 2023.

SYNOPSIS: A Phase II trial comparing subcutaneous (SC) administration of pooled immunoglobulin to intravenous (IV) administration of immunoglobulin in 23 patients with seropositive myasthenia gravis demonstrated a stable course after transition from IV to SC.

SOURCE: Pasnoor M, Bril V, Levine T, et al. Phase 2 trial in acetylcholine receptor antibody-positive myasthenia gravis of transition from intravenous to subcutaneous immunoglobulin: The MGSCIg study. Eur J Neurol 2023;30:1417-1424.